REVA to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum

SAN DIEGO, Nov. 02, 2017 -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that its Chief Financial Officer, Ms. Brandi Roberts, is scheduled to present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 9, 2017, at 10:00 a.m. US EST. The conference is being held at the Westin Grand Central in New York City.

The presentation materials delivered at the conference will be available in the Investor Relations section of REVA’s website at www.revamedical.com on the day of the presentation.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorobable polymer technologies for vascular applications. The Company’s lead product, the Fantom bioresorbable scaffold, received European CE Mark on April 3, 2017 for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the United States and Europe.

About Fantom

Fantom is a sirolimus-eluting bioresorbable scaffold developed as an alternative to metallic stents for the treatment of coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, and then disappear (or “resorb”) from the body over a period of time. This resorption is intended to allow the return of natural movement and function of the artery. Fantom is the only bioresorbable scaffold made from Tyrocore, REVA’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently radiopaque, making Fantom the first and only bioresorbable scaffold that is visible under fluoroscopy. Fantom is designed with thin struts while maintaining strength and with distinct ease-of-use features such as expansion with one continuous inflation.